- Home
- JFU vs PASG Comparison
JFU vs PASG Comparison
Compare JFU & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFU
- PASG
- Stock Information
- Founded
- JFU 2006
- PASG 2017
- Country
- JFU China
- PASG United States
- Employees
- JFU N/A
- PASG N/A
- Industry
- JFU Finance: Consumer Services
- PASG Biotechnology: Pharmaceutical Preparations
- Sector
- JFU Finance
- PASG Health Care
- Exchange
- JFU Nasdaq
- PASG Nasdaq
- Market Cap
- JFU 17.1M
- PASG 20.3M
- IPO Year
- JFU 2019
- PASG 2020
- Fundamental
- Price
- JFU $2.51
- PASG $7.18
- Analyst Decision
- JFU
- PASG Strong Buy
- Analyst Count
- JFU 0
- PASG 4
- Target Price
- JFU N/A
- PASG $59.25
- AVG Volume (30 Days)
- JFU 27.5K
- PASG 31.7K
- Earning Date
- JFU 01-01-0001
- PASG 08-12-2025
- Dividend Yield
- JFU N/A
- PASG N/A
- EPS Growth
- JFU N/A
- PASG N/A
- EPS
- JFU 0.58
- PASG N/A
- Revenue
- JFU $42,467,427.00
- PASG N/A
- Revenue This Year
- JFU N/A
- PASG N/A
- Revenue Next Year
- JFU N/A
- PASG N/A
- P/E Ratio
- JFU $4.36
- PASG N/A
- Revenue Growth
- JFU N/A
- PASG N/A
- 52 Week Low
- JFU $1.01
- PASG $5.12
- 52 Week High
- JFU $3.60
- PASG $26.60
- Technical
- Relative Strength Index (RSI)
- JFU 69.35
- PASG 53.33
- Support Level
- JFU $2.31
- PASG $6.65
- Resistance Level
- JFU $3.25
- PASG $7.54
- Average True Range (ATR)
- JFU 0.25
- PASG 0.56
- MACD
- JFU 0.02
- PASG 0.00
- Stochastic Oscillator
- JFU 47.52
- PASG 49.10
About JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company generates the majority of its revenue from Loan facilitation services. All its revenues are generated from the People's Republic of China.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.